-

08:27:09 AM

Latest NVCR Stock Market News

NVCR - NovoCure Ltd

09/14/21 7:00 AM

Nasdaq : NVCR

clinical trial

Novocure Announces Clinical Trial Collaboration with Roche to Evaluate Tumor Treating Fields as Part of a Novel Combination for the First-line Treatment of Metastatic Pancreatic Cancer

Novocure today announced it has entered into a clinical trial collaboration agreement with Roche, to develop Tumor Treating Fields together with Roche’ s anti-PD-L1 therapy, atezolizumab, in metastatic pancreatic ductal adenocarcinoma. “We are pleased to collaborate with Roche, a global leader in oncology, to explore the efficacy of TTFields together with...

RHEA-AI

neutral

09/09/21 8:14 AM

Nasdaq : NVCR

FDA Grants Breakthrough Device Designation to the NovoTTF-200T™ System for Advanced Liver Cancer

Novocure today announced the United States Food and Drug Administration has granted breakthrough designation to the NovoTTF-200T System, a Tumor Treating Fields delivery system intended for use together with atezolizumab and bevacizumab for the first-line treatment of patients with unresectable or metastatic liver cancer. The U.S. FDA has granted...

RHEA-AI

very positive

09/02/21 6:00 AM

Nasdaq : NVCR

conferences

Novocure to Participate in the 2021 Wells Fargo Virtual Healthcare Conference

Novocure announced today that Ashley Cordova, Chief Financial Officer, and Pritesh Shah, Chief Commercial Officer, will participate in the 2021 Wells Fargo Virtual Healthcare Conference on September 10, 2021. Ms. Cordova and Mr. Shah will take part in a fireside chat at 10:40 a.m. EDT. Ms. Cordova and Mr. Shah will also participate in one-on-one meetings with...

RHEA-AI

neutral

09/01/21 7:50 AM

Nasdaq : NVCR

management

Novocure Appoints Bill Burke as Chief Human Resources Officer

Novocure today announced that William Burke has been promoted to Chief Human Resources Officer, effective September 1, 2021. Mr. Burke joined Novocure in 2014 and most recently served as the Senior Vice President of Global Human Resources. Mr. Burke holds a bachelor’ s degree in Business and Industrial Relations from the University of Bridgeport, and he has...

RHEA-AI

neutral

07/29/21 6:00 AM

Nasdaq : NVCR

earnings

Novocure Reports Second Quarter 2021 Financial Results and Provides Company Update

Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended June 30, 2021, highlighting commercial strength and strategic investment across clinical, product development and commercial initiatives intended to fuel future growth. Novocure is a global oncology company working to

RHEA-AI

neutral

07/15/21 7:30 AM

Nasdaq : NVCR

Novocure Announces Recipients of 3rd Annual AACR-Novocure Grants for Tumor Treating Fields Research Program

Novocure (NASDAQ: NVCR) today announced the recipients of the 3rd Annual AACR-Novocure Grants for Tumor Treating Fields Research program. The program represents a joint effort between Novocure and the American Association for Cancer Research (AACR) to promote and support innovative research on

RHEA-AI

very positive

07/08/21 7:30 AM

Nasdaq : NVCR

conferencesearnings

Novocure to Report Second Quarter 2021 Financial Results

Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2021 on Thursday, July 29, 2021, before the U.S. financial markets open. Novocure’s management will host a conference call and webcast to discuss its financial results for the three and six months

RHEA-AI

neutral

07/01/21 7:15 AM

Nasdaq : NVCR

clinical trial

Novocure Presents Final Safety and Efficacy Results from its Phase 2 Pilot HEPANOVA Trial in Liver Cancer

Novocure (NASDAQ: NVCR) today announced final results from its phase 2 pilot HEPANOVA trial in liver cancer testing the safety and efficacy of Tumor Treating Fields (TTFields) together with sorafenib for the treatment of advanced hepatocellular cancer. In 21 evaluable patients, the disease control

RHEA-AI

neutral

06/16/21 7:30 AM

Nasdaq : NVCR

Novocure Initiates Usability Study for Flexible Torso Array

Novocure (NASDAQ: NVCR) today announced it has advanced a new, flexible torso array into a clinical usability study. The updated array will be tested by patients and their caregivers at four clinical sites in Europe.Novocure designed the array to improve patient comfort for all torso and

RHEA-AI

very positive

05/25/21 7:30 AM

Nasdaq : NVCR

clinical trial

Novocure Announces Clinical Trial Collaboration with GT Medical Technologies to Evaluate Tumor Treating Fields Together with GammaTile® Therapy in Recurrent Glioblastoma

Novocure (NASDAQ: NVCR) today announced it has entered into a clinical trial collaboration agreement with GT Medical Technologies, Inc., to develop Tumor Treating Fields (TTFields) together with GT Medical Technologies’ GammaTile Surgically Targeted Radiation Therapy (STaRT) for treatment of

RHEA-AI

very positive

NVCR Data:

IndustrySurgical and Medical Instrument Manufacturing
Websitewww.novocure.com
CeoAsaf Danziger
Security nameNovoCure Ltd
Issue typecs
SectorManufacturing
Sic code3841
Employees1023
Tags
- Health Technology
- Medical Specialties
- Manufacturing
- Surgical and Medical Instrument Manufacturing
AddressForum
StateSaint Helier
CityNo 4 Grenville Street
ZipJE2 4UF
CountryJersey
Phone441534756700

NVCR Description:

Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Tumor Treating Fields is a cancer therapy that uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Novocure's commercialized products are approved for the treatment of adult patients with glioblastoma and malignant pleural mesothelioma. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and liver cancer.